Q32 Bio — Third Quarter 2026 Earnings Summary

Q32 Bio reported third-quarter 2026 financial results showing a net loss of $8.9 million and cash and cash equivalents of $289.6 million as of September 30, 2026. The company presented 36-week efficacy data and 16-week off-drug findings from Part B of the SIGNAL-AA clinical trial for bempikibart, demonstrating a mean 35.3% reduction in SALT scores and robust durability of response. Q32 Bio plans to initiate a registration-directed program for severe or very severe alopecia areata in the first half of 2027 following regulatory discussions. Additionally, the company appointed José Trevejo as Chief Medical Officer and Ellie Hershberger as Chief Development Officer to lead late-stage development efforts.